Albireo presents new bylvay® (odevixibat) data at annual espghan congress

Boston, june 24, 2022 (globe newswire) -- albireo pharma, inc. (nasdaq: albo), a rare liver disease company developing novel bile acid modulators, today announced the presentation of new data at the annual meeting of the european society for paediatric gastroenterology, hepatology and nutrition (espghan) being held in copenhagen, denmark. the data provided new analyses of the phase 3 pedfic 1 and pedfic 2 trials of bylvay® (odevixibat), demonstrating that dose escalation can provide greater benefits in relieving patients' pruritus, with similar tolerability, as well as showing that reductions in pruritus are associated with important improvements in sleep and other quality of life measures in children with all types of progressive familial intrahepatic cholestasis (pfic).
ALBO Ratings Summary
ALBO Quant Ranking